Tags

Type your tag names separated by a space and hit enter

Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation.
Nutr Metab Cardiovasc Dis. 2016 Mar; 26(3):254-60.NM

Abstract

BACKGROUND AND AIMS

Circulating microparticles (MP) are the source of a plasma derived form of the scavenger receptor CD36, termed soluble (s)CD36, the levels of which correlate with markers of atherosclerosis and risk of cardiovascular disease. Long chain n-3 polyunsaturated fatty acids have cardioprotective effects that we have previously reported to be gender specific. The aim of this study was to determine if dietary docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) supplementation affect circulating CD36 + MP levels, and if this occurs differentially in healthy men and women.

METHODS AND RESULTS

Participants (43M, 51F) aged 39.6 ± 1.7 years received 4 weeks of daily supplementation with DHA rich (200 mg EPA; 1000 mg DHA), EPA rich (1000 mg EPA; 200 mg DHA), or placebo (sunola) oil in a double-blinded, randomised, placebo controlled trial. Plasma CD36 + MP were enumerated by flow cytometry and differences between genders and treatments were evaluated by Student's or paired t-test and one way ANOVA. Males and females had similar levels of CD36 + MP at baseline (mean = 1018 ± 325 vs 980 ± 318; p = 0.577) and these were not significantly changed after DHA (M, p = 0.571; F, p = 0.444) or EPA (M, p = 0.361; F, p = 0.901) supplementation. Likewise, the overall percent change in these levels were not different between supplemented cohorts compared to placebo when all participants were combined (% change in CD36 + MP: DHA = 5.7 ± 37.5, EPA = -3.4 ± 35.4, placebo = -11.5 ± 32.9; p = 0.158) or stratified by gender (M, DHA = -2.6 ± 30.6, EPA = -15.1 ± 20.1, placebo = -21.4 ± 28.7, p = 0.187; F, DHA = 11.7 ± 41.5, EPA = 6.8 ± 42.9, placebo = -2.8 ± 34.7, p = 0.552).

CONCLUSION

The cardioprotective effects of DHA and EPA do not act through a CD36 + MP mechanism.

Authors+Show Affiliations

Nutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia.School of Environmental and Life Sciences, University of Newcastle, Ourimbah, NSW 2258, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.Nutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW 2308, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia.Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia; Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia. Electronic address: lisa.lincz@newcastle.edu.au.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26803595

Citation

Phang, M, et al. "Circulating CD36+ Microparticles Are Not Altered By Docosahexaenoic or Eicosapentaenoic Acid Supplementation." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 26, no. 3, 2016, pp. 254-60.
Phang M, Thorne RF, Alkhatatbeh MJ, et al. Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation. Nutr Metab Cardiovasc Dis. 2016;26(3):254-60.
Phang, M., Thorne, R. F., Alkhatatbeh, M. J., Garg, M. L., & Lincz, L. F. (2016). Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 26(3), 254-60. https://doi.org/10.1016/j.numecd.2015.12.003
Phang M, et al. Circulating CD36+ Microparticles Are Not Altered By Docosahexaenoic or Eicosapentaenoic Acid Supplementation. Nutr Metab Cardiovasc Dis. 2016;26(3):254-60. PubMed PMID: 26803595.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation. AU - Phang,M, AU - Thorne,R F, AU - Alkhatatbeh,M J, AU - Garg,M L, AU - Lincz,L F, Y1 - 2015/12/18/ PY - 2015/07/21/received PY - 2015/11/20/revised PY - 2015/12/10/accepted PY - 2016/1/25/entrez PY - 2016/1/25/pubmed PY - 2016/12/22/medline KW - CD36 KW - Docosahexaenoic acid KW - Eicosapentaenoic acid KW - Microparticles KW - Polyunsaturated fatty acids KW - Scavenger receptor SP - 254 EP - 60 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 26 IS - 3 N2 - BACKGROUND AND AIMS: Circulating microparticles (MP) are the source of a plasma derived form of the scavenger receptor CD36, termed soluble (s)CD36, the levels of which correlate with markers of atherosclerosis and risk of cardiovascular disease. Long chain n-3 polyunsaturated fatty acids have cardioprotective effects that we have previously reported to be gender specific. The aim of this study was to determine if dietary docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) supplementation affect circulating CD36 + MP levels, and if this occurs differentially in healthy men and women. METHODS AND RESULTS: Participants (43M, 51F) aged 39.6 ± 1.7 years received 4 weeks of daily supplementation with DHA rich (200 mg EPA; 1000 mg DHA), EPA rich (1000 mg EPA; 200 mg DHA), or placebo (sunola) oil in a double-blinded, randomised, placebo controlled trial. Plasma CD36 + MP were enumerated by flow cytometry and differences between genders and treatments were evaluated by Student's or paired t-test and one way ANOVA. Males and females had similar levels of CD36 + MP at baseline (mean = 1018 ± 325 vs 980 ± 318; p = 0.577) and these were not significantly changed after DHA (M, p = 0.571; F, p = 0.444) or EPA (M, p = 0.361; F, p = 0.901) supplementation. Likewise, the overall percent change in these levels were not different between supplemented cohorts compared to placebo when all participants were combined (% change in CD36 + MP: DHA = 5.7 ± 37.5, EPA = -3.4 ± 35.4, placebo = -11.5 ± 32.9; p = 0.158) or stratified by gender (M, DHA = -2.6 ± 30.6, EPA = -15.1 ± 20.1, placebo = -21.4 ± 28.7, p = 0.187; F, DHA = 11.7 ± 41.5, EPA = 6.8 ± 42.9, placebo = -2.8 ± 34.7, p = 0.552). CONCLUSION: The cardioprotective effects of DHA and EPA do not act through a CD36 + MP mechanism. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/26803595/Circulating_CD36+_microparticles_are_not_altered_by_docosahexaenoic_or_eicosapentaenoic_acid_supplementation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(15)30122-8 DB - PRIME DP - Unbound Medicine ER -